NO-tissue plasminogen activator

Drug Profile

NO-tissue plasminogen activator

Alternative Names: NO-tPA

Latest Information Update: 19 Mar 2008

Price : $50

At a glance

  • Originator NitroMed
  • Class Plasminogen activator enzymes
  • Mechanism of Action Fibrinolytic agents; Nitric oxide donors; Plasminogen activator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Coronary artery restenosis; Myocardial infarction

Most Recent Events

  • 06 Mar 2008 NitroMed's nitric oxide-enhancing technologies are available for licensing
  • 28 Sep 1999 Preclinical development for Coronary artery restenosis in USA (Parenteral)
  • 28 Sep 1999 Preclinical development for Myocardial infarction in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top